Dr. Sims is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
705 Riley Hospital Dr
Indianapolis, IN 46202Phone+1 317-944-3889Fax+1 317-944-3882- Is this information wrong?
Summary
- Dr. Emily K. Sims MD, MS is a physician scientist specializing in pediatric endocrinology, with a long-term goal of addressing clinically relevant problems in diabetes utilizing molecular discovery. Her research focus revolves around the investigation of molecular mechanisms contributing to β cell dysfunction and the development of diabetes, the identification and verification of circulating biomarkers of β cell dysfunction, and clinical studies identifying and targeting β cell dysfunction in T1D. She hopes to ultimately utilize knowledge gained for development of biomarkers and β cell-targeted therapeutics that allow for a more tailored approach to treatment of patients with or at-risk for diabetes.
Education & Training
- Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2013
- University of Alabama School of MedicineClass of 2007
Certifications & Licensure
- IN State Medical License 2010 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Endocrinology
Publications & Presentations
PubMed
- Comparisons of Metabolic Measures to Predict T1D vs. Detect a Preventive Treatment Effect in High-Risk Individuals.Cuthbertson, D., Jacobsen, L., Nathan, B., Redondo, M., Sims, E., Ismail, H., Herold, K., Sosenko, J.> ;The Journal of Clinical Endocrinology and Metabolism. 2024 Jan 24
- 1 citationsInhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.Emily K Sims, Abhishek Kulkarni, Audrey Hull, Stephanie E Woerner, Susanne Cabrera, Lucy D Mastrandrea, Batoul Hammoud, Soumyadeep Sarkar, Ernesto S Nakayasu, Teresa L...> ;Cell Reports. Medicine. 2023 Nov 21
- High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab trea...Emily K Sims, Susan M Geyer, S Alice Long, Kevan C Herold> ;Diabetologia. 2023 Dec 1
- Join now to see all
Press Mentions
- Type 1 Diabetes: Recent Wins and Ongoing Challenges on the Road to a CureMay 24th, 2023
- IU Research Contributes to First FDA-approved Drug to Delay Onset of Type 1 DiabetesNovember 21st, 2022
- FDA Approves First-Ever Agent to Delay Type 1 Diabetes OnsetNovember 18th, 2022
- Join now to see all
Hospital Affiliations
- Indiana University Health North HospitalCarmel, Indiana
- Riley Hospital for Children at IU HealthIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: